Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xoma Royalty Corporation (XOMA)

Xoma Royalty Corporation (XOMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 363,565
  • Shares Outstanding, K 12,383
  • Annual Sales, $ 28,490 K
  • Annual Income, $ -13,820 K
  • EBIT $ 4 M
  • EBITDA $ 4 M
  • 60-Month Beta 0.89
  • Price/Sales 38.36
  • Price/Cash Flow N/A
  • Price/Book 3.68

Options Overview Details

View History
  • Implied Volatility 100.02% (-23.41%)
  • Historical Volatility 100.17%
  • IV Percentile 79%
  • IV Rank 43.99%
  • IV High 172.07% on 12/12/25
  • IV Low 43.42% on 08/18/25
  • Expected Move (DTE 1) 2.26 (7.70%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 131
  • Volume Avg (30-Day) 259
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 895
  • Open Int (30-Day) 448
  • Expected Range 27.10 to 31.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.04
  • Number of Estimates 2
  • High Estimate 0.05
  • Low Estimate -0.12
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +91.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.40 +20.33%
on 01/12/26
30.79 -4.64%
on 01/09/26
+4.14 (+16.42%)
since 12/12/25
3-Month
24.40 +20.33%
on 01/12/26
39.00 -24.72%
on 10/16/25
-7.65 (-20.67%)
since 10/14/25
52-Week
18.35 +59.98%
on 04/07/25
39.92 -26.45%
on 10/03/25
+2.65 (+9.92%)
since 01/14/25

Most Recent Stories

More News
XOMA Royalty Announces CFO Transition

EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from...

XOMA : 29.36 (+8.18%)
XOMAP : 26.12 (-1.43%)
XOMAO : 25.41 (+0.47%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ: XOMA). Such investors are advised...

XOMA : 29.36 (+8.18%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

NEW YORK , Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ: XOMA). Such investors are advised...

XOMA : 29.36 (+8.18%)
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab

– Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) – – XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with...

XOMA : 29.36 (+8.18%)
XOMAP : 26.12 (-1.43%)
XOMAO : 25.41 (+0.47%)
XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized the following cash...

XOMA : 29.36 (+8.18%)
XOMAP : 26.12 (-1.43%)
XOMAO : 25.41 (+0.47%)
XOMA Royalty Enters into Agreement to Acquire Generation Bio

- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna - - Generation Bio’s cell-targeted lipid nanoparticles (ctLNP)...

GBIO : 5.65 (+0.36%)
XOMA : 29.36 (+8.18%)
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously...

XOMA : 29.36 (+8.18%)
XOMAP : 26.12 (-1.43%)
XOMAO : 25.41 (+0.47%)
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition

WALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“ Mural ”) announces that the scheme of arrangement between Mural and its shareholders under Chapter...

XOMA : 29.36 (+8.18%)
MURA : 2.04 (unch)
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty

WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) (“ Mural ”) announces that, in accordance with the terms of the transaction agreement between...

XOMA : 29.36 (+8.18%)
MURA : 2.04 (unch)
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

EMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) today announced it has successfully completed its previously announced acquisition of...

XOMA : 29.36 (+8.18%)
XOMAP : 26.12 (-1.43%)
XOMAO : 25.41 (+0.47%)
LVTX : 1.7400 (-3.87%)

Business Summary

XOMA ROYALTY is a biotechnology royalty aggregator. The company acquires the potential future economics associated with pre-commercial therapeutic candidates which have been licensed to pharmaceutical or biotechnology companies. XOMA ROYALTY, formerly known as XOMA Corporation, is based in EMERYVILLE,...

See More

Key Turning Points

3rd Resistance Point 32.96
2nd Resistance Point 31.20
1st Resistance Point 30.28
Last Price 29.36
1st Support Level 27.60
2nd Support Level 25.84
3rd Support Level 24.92

See More

52-Week High 39.92
Fibonacci 61.8% 31.68
Last Price 29.36
Fibonacci 50% 29.14
Fibonacci 38.2% 26.59
52-Week Low 18.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar